Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH-R in Aggressive Non-Hodgkin's Lymphoma
NCT00001337Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 1993
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in primary mediastinal large B-cell lymphoma (PMBCL), mediastinal gray zone lymphoma (MGZL), sponsored by National Cancer Institute. Started May 1993; status: completed.
02
Drugs
rituximab
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)mediastinal gray zone lymphoma (MGZL)
Beyond the preview
Go deeper on NCT00001337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001337.